Vitae May Look To Public Markets After Nearly A Decade Of Self-Sustained Growth
This article was originally published in The Pink Sheet Daily
Executive Summary
Alzheimer’s collaboration with Boehringer Ingelheim heads into the clinic, triggering a $14 million milestone payment to Vitae. But as the discovery specialist focuses more on autoimmune conditions and less on primary care, it also may want to increase involvement in clinical development and even commercialization of its discoveries.